United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

baxter healthcare ltd - cyclophosphamide monohydrate - oral tablet - 50mg

Australia - English - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - cyclophosphamide monohydrate, quantity: 53.5 mg (equivalent: cyclophosphamide, qty 50 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; magnesium stearate; croscarmellose sodium; titanium dioxide; hypromellose; iron oxide yellow; macrogol 6000; iron oxide red; iron oxide black; ethylcellulose - indications as at 18 december 2002 : the proper use of cyclophosphamide requires accurate diagnosis, careful assessment of the anatomic extent of the disease, knowledge of the type and effects of any previous therapy and continued evaluation of the patient's general and haematological status. it is essential that adequate clinical and laboratory facilities be available for proper monitoring of patients during treatment with cyclophosphamide. the clinical course of the disease should be recorded in objective terms before treatment is begun and thereafter at regular intervals. careful management of patients receiving cyclophosphamide will help achieve maximum benefit with minimum risk. antineoplastic properties: patients with neoplasms that might preferably be treated by surgical and/or irradiation procedures should ordinarily not be treated by chemotherapy alone. the following classification is a guide to the various neoplastic conditions in which benefit may be derived from chemotherapy with cyclophosphamide. (a) frequently responsive myeloproliferative and lymphoproliferative disorders: malignant lymphomas (stages iii and iv, peter's staging system*); multiple myeloma; leukaemias; mycosis fungoides (advanced disease). * modified as the international staging classification for hodgkin's disease in "report of the committee on the staging of hodgkin's disease." cancer res. 26, 1310, 1966. stage i. disease limited to one anatomic region (stage i) or two contiguous anatomic regions (stage i) on the same side of the diaphragm. stage ii. disease in more than two anatomic regions or in two contiguous regions on the same side of the diaphragm. stage iii. disease on both sides of the diaphragm, but not extending beyond the involvement of the lymph nodes, spleen and/or tonsils. stage iv. involvement of the bone marrow, lung parenchyma, pleura, liver, bone, skin, kidneys, gastrointestinal tract, or any tissue or organ in addition to lymph nodes, spleen or tonsils. all stages are sub classified as a or b to indicate the absence or presence respectively of systemic symptoms. (b) frequently responsive solid malignancies: neuroblastoma (patients with disseminated disease); adenocarcinoma of the ovary; retinoblastoma. (c) infrequently responsive malignancies: carcinoma of the breast; malignant neoplasm of the lung. immunosuppressive properties: cyclophosphamide has been used in the treatment of autoimmune diseases and immunopathies of unspecified type (i.e. wegener's granulomatosis) when these diseases have been resistant to the conventional first and second line treatment and for the prevention of transplant rejection. cyclophosphamide can be recommended for use in the treatment of non-malignancies only when in the opinion of the physician the benefits to the patient outweigh the risk of treatment with cyclophosphamide.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - cyclophosphamide (unii: 8n3dw7272p) (cyclophosphamide - unii:8n3dw7272p) - cyclophosphamide 25 mg - cyclophosphamide tablets usp, 25 mg and 50 mg, although effective alone in susceptible malignancies, are more frequently used concurrently or sequentially with other antineoplastic drugs. the following malignancies are often susceptible to cyclophosphamide treatment: - malignant lymphomas (stages iii and iv of the ann arbor staging system), hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, burkitt’s lymphoma. - multiple myeloma. - leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children (cyclophosphamide given during remission is effective in prolonging its duration). - mycosis fungoides (advanced disease). - neuroblastoma (disseminated disease). - adenocarcinoma of the ovary. - retinoblastoma. - carcinoma of the breast. cyclophosphamide tablets usp, 25 mg and 50 mg are useful in carefully s

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - cyclophosphamide, quantity: 2000 mg (equivalent: cyclophosphamide monohydrate, qty mg) - injection, powder for - excipient ingredients: mannitol - the proper use of cyclophosphamide requires accurate diagnosis, careful assessment of the anatomic extent of the disease, knowledge of the type and effects of any previous therapy, and continued evaluation of the patient?s general and haematologic status. it is essential that adequate clinical and laboratory facilities be available for proper monitoring of patients during treatment with cyclophosphamide.,the clinical course of the disease should be recorded in objective terms before treatment is begun and thereafter at regular intervals. careful management of patients receiving cyclophosphamide will help achieve maximum benefit with minimum risk.,antineoplastic properties patients with neoplasms that might preferably be treated by surgical and/or irradiation procedures should ordinarily not be treated by chemotherapy alone.,the following classification is a guide to the various neoplastic conditions in which benefit may be derived from chemotherapy with cyclophosphamide:,frequently responsive myeloproliferative and lymphoproliferative disorders: malignant lymphomas including hodgkins (stages iii and iv, peter?s staging system*) and non-hodgkins lymphomas; multiple myeloma; leukaemias; mycosis fungoides (advanced disease).,stage i: disease limited to one anatomic region (stage i) or two contiguous anatomic regions (stage i2) on the same side of the diaphragm.,* modified as the international staging classification for hodgkin?s disease in ?report of the committee on the staging of hodgkin?s disease?. cancer res 26:1310, 1966.,stage ii: disease in more than two anatomic regions or two contiguous regions on the same side of the diaphragm.,stage iii: disease on both sides of the diaphragm, but not extending beyond the involvement of lymph nodes, spleen, and/or waldeyer?s ring.,stage iv: involvement of the bone marrow, lung parenchyma, pleura, liver, bone, skin, kidneys, gastrointestinal tract, or in any tissue or organ in addition to lymph nodes, spleen or waldeyer?s ring.,all stages are subclassified as a or b to indicate the absence or presence, respectively, of systemic symptoms.,frequently responsive solid malignancies: neuroblastoma (patients with disseminated disease); adenocarcinoma of the ovary, retinoblastoma.,infrequently responsive malignancies: carcinoma of the breast; malignant neoplasms of the lung.,immunosuppressive properties,cyclophosphamide has also been used in the treatment of autoimmune diseases and immunopathies of unspecified type (ie wegener?s granulomatosis) when these diseases have been resistant to conventional first and second line of treatment, and for the prevention of transplant rejection. cyclophosphamide can be recommended for use in treatment of nonmalignancies only when in the opinion of the physician the benefits to the patient outweigh the risk of treatment with cyclophosphamide.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - cyclophosphamide, quantity: 500 mg (equivalent: cyclophosphamide monohydrate, qty mg) - injection, powder for - excipient ingredients: mannitol - the proper use of cyclophosphamide requires accurate diagnosis, careful assessment of the anatomic extent of the disease, knowledge of the type and effects of any previous therapy, and continued evaluation of the patient?s general and haematologic status. it is essential that adequate clinical and laboratory facilities be available for proper monitoring of patients during treatment with cyclophosphamide.,the clinical course of the disease should be recorded in objective terms before treatment is begun and thereafter at regular intervals. careful management of patients receiving cyclophosphamide will help achieve maximum benefit with minimum risk.,antineoplastic properties patients with neoplasms that might preferably be treated by surgical and/or irradiation procedures should ordinarily not be treated by chemotherapy alone.,the following classification is a guide to the various neoplastic conditions in which benefit may be derived from chemotherapy with cyclophosphamide:,frequently responsive myeloproliferative and lymphoproliferative disorders: malignant lymphomas including hodgkins (stages iii and iv, peter?s staging system*) and non-hodgkins lymphomas; multiple myeloma; leukaemias; mycosis fungoides (advanced disease).,stage i: disease limited to one anatomic region (stage i) or two contiguous anatomic regions (stage i2) on the same side of the diaphragm.,* modified as the international staging classification for hodgkin?s disease in ?report of the committee on the staging of hodgkin?s disease?. cancer res 26:1310, 1966.,stage ii: disease in more than two anatomic regions or two contiguous regions on the same side of the diaphragm.,stage iii: disease on both sides of the diaphragm, but not extending beyond the involvement of lymph nodes, spleen, and/or waldeyer?s ring.,stage iv: involvement of the bone marrow, lung parenchyma, pleura, liver, bone, skin, kidneys, gastrointestinal tract, or in any tissue or organ in addition to lymph nodes, spleen or waldeyer?s ring.,all stages are subclassified as a or b to indicate the absence or presence, respectively, of systemic symptoms.,frequently responsive solid malignancies: neuroblastoma (patients with disseminated disease); adenocarcinoma of the ovary, retinoblastoma.,infrequently responsive malignancies: carcinoma of the breast; malignant neoplasms of the lung.,immunosuppressive properties,cyclophosphamide has also been used in the treatment of autoimmune diseases and immunopathies of unspecified type (ie wegener?s granulomatosis) when these diseases have been resistant to conventional first and second line of treatment, and for the prevention of transplant rejection. cyclophosphamide can be recommended for use in treatment of nonmalignancies only when in the opinion of the physician the benefits to the patient outweigh the risk of treatment with cyclophosphamide.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - cyclophosphamide, quantity: 1000 mg (equivalent: cyclophosphamide monohydrate, qty mg) - injection, powder for - excipient ingredients: mannitol - the proper use of cyclophosphamide requires accurate diagnosis, careful assessment of the anatomic extent of the disease, knowledge of the type and effects of any previous therapy, and continued evaluation of the patient?s general and haematologic status. it is essential that adequate clinical and laboratory facilities be available for proper monitoring of patients during treatment with cyclophosphamide.,the clinical course of the disease should be recorded in objective terms before treatment is begun and thereafter at regular intervals. careful management of patients receiving cyclophosphamide will help achieve maximum benefit with minimum risk.,antineoplastic properties patients with neoplasms that might preferably be treated by surgical and/or irradiation procedures should ordinarily not be treated by chemotherapy alone.,the following classification is a guide to the various neoplastic conditions in which benefit may be derived from chemotherapy with cyclophosphamide:,frequently responsive myeloproliferative and lymphoproliferative disorders: malignant lymphomas including hodgkins (stages iii and iv, peter?s staging system*) and non-hodgkins lymphomas; multiple myeloma; leukaemias; mycosis fungoides (advanced disease).,stage i: disease limited to one anatomic region (stage i) or two contiguous anatomic regions (stage i2) on the same side of the diaphragm.,* modified as the international staging classification for hodgkin?s disease in ?report of the committee on the staging of hodgkin?s disease?. cancer res 26:1310, 1966.,stage ii: disease in more than two anatomic regions or two contiguous regions on the same side of the diaphragm.,stage iii: disease on both sides of the diaphragm, but not extending beyond the involvement of lymph nodes, spleen, and/or waldeyer?s ring.,stage iv: involvement of the bone marrow, lung parenchyma, pleura, liver, bone, skin, kidneys, gastrointestinal tract, or in any tissue or organ in addition to lymph nodes, spleen or waldeyer?s ring.,all stages are subclassified as a or b to indicate the absence or presence, respectively, of systemic symptoms.,frequently responsive solid malignancies: neuroblastoma (patients with disseminated disease); adenocarcinoma of the ovary, retinoblastoma.,infrequently responsive malignancies: carcinoma of the breast; malignant neoplasms of the lung.,immunosuppressive properties,cyclophosphamide has also been used in the treatment of autoimmune diseases and immunopathies of unspecified type (ie wegener?s granulomatosis) when these diseases have been resistant to conventional first and second line of treatment, and for the prevention of transplant rejection. cyclophosphamide can be recommended for use in treatment of nonmalignancies only when in the opinion of the physician the benefits to the patient outweigh the risk of treatment with cyclophosphamide.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - cyclophosphamide, quantity: 2000 mg (equivalent: cyclophosphamide monohydrate, qty mg) - injection, powder for - excipient ingredients: mannitol - the proper use of cyclophosphamide requires accurate diagnosis, careful assessment of the anatomic extent of the disease, knowledge of the type and effects of any previous therapy, and continued evaluation of the patient?s general and haematologic status. it is essential that adequate clinical and laboratory facilities be available for proper monitoring of patients during treatment with cyclophosphamide.,the clinical course of the disease should be recorded in objective terms before treatment is begun and thereafter at regular intervals. careful management of patients receiving cyclophosphamide will help achieve maximum benefit with minimum risk.,antineoplastic properties patients with neoplasms that might preferably be treated by surgical and/or irradiation procedures should ordinarily not be treated by chemotherapy alone.,the following classification is a guide to the various neoplastic conditions in which benefit may be derived from chemotherapy with cyclophosphamide:,frequently responsive myeloproliferative and lymphoproliferative disorders: malignant lymphomas including hodgkins (stages iii and iv, peter?s staging system*) and non-hodgkins lymphomas; multiple myeloma; leukaemias; mycosis fungoides (advanced disease).,stage i: disease limited to one anatomic region (stage i) or two contiguous anatomic regions (stage i2) on the same side of the diaphragm.,* modified as the international staging classification for hodgkin?s disease in ?report of the committee on the staging of hodgkin?s disease?. cancer res 26:1310, 1966.,stage ii: disease in more than two anatomic regions or two contiguous regions on the same side of the diaphragm.,stage iii: disease on both sides of the diaphragm, but not extending beyond the involvement of lymph nodes, spleen, and/or waldeyer?s ring.,stage iv: involvement of the bone marrow, lung parenchyma, pleura, liver, bone, skin, kidneys, gastrointestinal tract, or in any tissue or organ in addition to lymph nodes, spleen or waldeyer?s ring.,all stages are subclassified as a or b to indicate the absence or presence, respectively, of systemic symptoms.,frequently responsive solid malignancies: neuroblastoma (patients with disseminated disease); adenocarcinoma of the ovary, retinoblastoma.,infrequently responsive malignancies: carcinoma of the breast; malignant neoplasms of the lung.,immunosuppressive properties,cyclophosphamide has also been used in the treatment of autoimmune diseases and immunopathies of unspecified type (ie wegener?s granulomatosis) when these diseases have been resistant to conventional first and second line of treatment, and for the prevention of transplant rejection. cyclophosphamide can be recommended for use in treatment of nonmalignancies only when in the opinion of the physician the benefits to the patient outweigh the risk of treatment with cyclophosphamide.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - cyclophosphamide, quantity: 1000 mg (equivalent: cyclophosphamide monohydrate, qty mg) - injection, powder for - excipient ingredients: mannitol - the proper use of cyclophosphamide requires accurate diagnosis, careful assessment of the anatomic extent of the disease, knowledge of the type and effects of any previous therapy, and continued evaluation of the patient?s general and haematologic status. it is essential that adequate clinical and laboratory facilities be available for proper monitoring of patients during treatment with cyclophosphamide.,the clinical course of the disease should be recorded in objective terms before treatment is begun and thereafter at regular intervals. careful management of patients receiving cyclophosphamide will help achieve maximum benefit with minimum risk.,antineoplastic properties patients with neoplasms that might preferably be treated by surgical and/or irradiation procedures should ordinarily not be treated by chemotherapy alone.,the following classification is a guide to the various neoplastic conditions in which benefit may be derived from chemotherapy with cyclophosphamide:,frequently responsive myeloproliferative and lymphoproliferative disorders: malignant lymphomas including hodgkins (stages iii and iv, peter?s staging system*) and non-hodgkins lymphomas; multiple myeloma; leukaemias; mycosis fungoides (advanced disease).,stage i: disease limited to one anatomic region (stage i) or two contiguous anatomic regions (stage i2) on the same side of the diaphragm.,* modified as the international staging classification for hodgkin?s disease in ?report of the committee on the staging of hodgkin?s disease?. cancer res 26:1310, 1966.,stage ii: disease in more than two anatomic regions or two contiguous regions on the same side of the diaphragm.,stage iii: disease on both sides of the diaphragm, but not extending beyond the involvement of lymph nodes, spleen, and/or waldeyer?s ring.,stage iv: involvement of the bone marrow, lung parenchyma, pleura, liver, bone, skin, kidneys, gastrointestinal tract, or in any tissue or organ in addition to lymph nodes, spleen or waldeyer?s ring.,all stages are subclassified as a or b to indicate the absence or presence, respectively, of systemic symptoms.,frequently responsive solid malignancies: neuroblastoma (patients with disseminated disease); adenocarcinoma of the ovary, retinoblastoma.,infrequently responsive malignancies: carcinoma of the breast; malignant neoplasms of the lung.,immunosuppressive properties,cyclophosphamide has also been used in the treatment of autoimmune diseases and immunopathies of unspecified type (ie wegener?s granulomatosis) when these diseases have been resistant to conventional first and second line of treatment, and for the prevention of transplant rejection. cyclophosphamide can be recommended for use in treatment of nonmalignancies only when in the opinion of the physician the benefits to the patient outweigh the risk of treatment with cyclophosphamide.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - cyclophosphamide, quantity: 500 mg (equivalent: cyclophosphamide monohydrate, qty mg) - injection, powder for - excipient ingredients: mannitol - the proper use of cyclophosphamide requires accurate diagnosis, careful assessment of the anatomic extent of the disease, knowledge of the type and effects of any previous therapy, and continued evaluation of the patient?s general and haematologic status. it is essential that adequate clinical and laboratory facilities be available for proper monitoring of patients during treatment with cyclophosphamide.,the clinical course of the disease should be recorded in objective terms before treatment is begun and thereafter at regular intervals. careful management of patients receiving cyclophosphamide will help achieve maximum benefit with minimum risk.,antineoplastic properties patients with neoplasms that might preferably be treated by surgical and/or irradiation procedures should ordinarily not be treated by chemotherapy alone.,the following classification is a guide to the various neoplastic conditions in which benefit may be derived from chemotherapy with cyclophosphamide:,frequently responsive myeloproliferative and lymphoproliferative disorders: malignant lymphomas including hodgkins (stages iii and iv, peter?s staging system*) and non-hodgkins lymphomas; multiple myeloma; leukaemias; mycosis fungoides (advanced disease).,stage i: disease limited to one anatomic region (stage i) or two contiguous anatomic regions (stage i2) on the same side of the diaphragm.,* modified as the international staging classification for hodgkin?s disease in ?report of the committee on the staging of hodgkin?s disease?. cancer res 26:1310, 1966.,stage ii: disease in more than two anatomic regions or two contiguous regions on the same side of the diaphragm.,stage iii: disease on both sides of the diaphragm, but not extending beyond the involvement of lymph nodes, spleen, and/or waldeyer?s ring.,stage iv: involvement of the bone marrow, lung parenchyma, pleura, liver, bone, skin, kidneys, gastrointestinal tract, or in any tissue or organ in addition to lymph nodes, spleen or waldeyer?s ring.,all stages are subclassified as a or b to indicate the absence or presence, respectively, of systemic symptoms.,frequently responsive solid malignancies: neuroblastoma (patients with disseminated disease); adenocarcinoma of the ovary, retinoblastoma.,infrequently responsive malignancies: carcinoma of the breast; malignant neoplasms of the lung.,immunosuppressive properties,cyclophosphamide has also been used in the treatment of autoimmune diseases and immunopathies of unspecified type (ie wegener?s granulomatosis) when these diseases have been resistant to conventional first and second line of treatment, and for the prevention of transplant rejection. cyclophosphamide can be recommended for use in treatment of nonmalignancies only when in the opinion of the physician the benefits to the patient outweigh the risk of treatment with cyclophosphamide.

United States - English - NLM (National Library of Medicine)

evereen shanghai biotechnology ltd. - cyclophosphamide (unii: 8n3dw7272p) (cyclophosphamide anhydrous - unii:6uxw23996m) -